Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 112

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 112
---
 ● | Our ability to establish an effective sales, marketing and distribution infrastructure in a timely manner; |

| ● | market acceptance of our product candidates, if approved, and our ability to forecast demand for those product candidates; |

| ● | Our ability to receive approval and commercialize product candidates outside of the United States; |

| ● | Our ability to establish and maintain collaborations, licensing or other arrangements; |

| ● | Our ability and third parties’ abilities to protect intellectual property rights; |

| ● | costs related to and outcomes of potential litigation or other disputes; |

| ● | Our ability to adequately support future growth; |

| ● | Our ability to attract and retain key personnel to manage our business effectively; |

| ● | potential liabilities associated with hazardous materials; |

| ● | Our ability to maintain adequate insurance policies; and |

| ● | future accounting pronouncements or changes in our accounting policies. |

The cumulative effect of such factors could result in large fluctuations and unpredictability in quarterly and annual operating results. As a result, comparing operating results on a period-to-period basis may not be meaningful. Investors should not rely on past results as an indication of future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our Common Stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide. Anti-takeover provisions under our organizational documents and Delaware law could delay or prevent a change of control which could limit the market price of our Common Stock and may prevent or frustrate attempts by our stockholders to replace or remove our then-current management. Our Charter and Bylaws, contain provisions that could delay or prevent a change of control of our board of directors that our stockholders might consider favorable. Some of these provisions include:

| ● | a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board of directors will be elected at one time; |

| ● | a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; |

| ● | a requirement that special meetings of stockholders be called only by the chairperson